In his most entertaining and scholarly letter, Diskin correctly characterizes the study of Roos et al1 as a randomized, prospective double-blind trial, and he is more than willing to accept its conclusions (in spite of the shortcomings pointed out in my editorial2), while he decries the growing use of practice guidelines. The inconsistency relates to the fact that practice guidelines are generally derived from critical analyses by acknowledged experts of not one but many randomized, prospective, double-blind trials. Thus, the basis for my recommendations is to subscribe to the larger scientific portfolio, whereas to do otherwise would clearly risk being the one “leaving early” from the scientific revolution. As an apparent student of medical history in general, and the writings of William Osler in particular, Diskin might do well to recall the admonition of Osler (that originated with Alexander Pope) to “be not the first by whom the new are tried, nor yet the last to lay the old aside.” Yes, the “standard of care” definition does relate to prudent physicians of comparable training in the same community, but prudence dictates that they primum non nocere. The reader is referred back to my editorial2 for the arguments that I believe support the traditional approach to initiation of levothyroxine therapy. However, I will reemphasize that both the early high-dose group and the control group in the study by Roos et al1 reported improvement in symptoms at the same rate—so what was gained other than risk of an adverse outcome? And if Diskin is implying that I had advocated a “monolithic” standard of care, I invite him to reread my Editorial and not rush to judgment. Finally, I will take the liberty of inferring that Diskin's characterization of “wisdom from the Ancients” constituted an ad hominem attribution and if so, I am grateful at least for the “wisdom” component.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.